# US 2015/0031728 A1 · Cyclooxygenase Inhibitor and Calcium Channel Antagonist Compositions and Methods for Use in Urological Procedures

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0031728 A1
- Document ID: US20150031728A1
- Status: Published application
- Kind: A1
- Application number: 14/316,008
- Filed: 2014-06-26
- Published: 2015-01-29
- Earliest claimed: 2005-05-20
- Assignees: Omeros Corporation
- Applicants: Omeros Corporation
- Inventors: Gregory A. Demopulos; Jeffrey M. Herz; Wayne R. Gombotz; Hui-rong Shen
- Web page: https://patentgrep.com/patent/US20150031728A1

## CPC

- A61K 31/4422: 1,4-Dihydropyridines, e.g. nifedipine, nicardipine
- A61K 9/0034: {Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 31/21: Esters, e.g. nitroglycerine, selenocyanates
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/455: Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A61L 31/16: Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)}
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 13/06: Anti-spasmodics
- A61P 13/10: of the bladder
- A61P 13/12: of the kidneys
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61L 2300/402: Anaestetics, analgesics, e.g. lidocaine
- A61L 2300/41: Anti-inflammatory agents, e.g. NSAIDs
- A61L 2300/432: Inhibitors, antagonists (A61L2300/402 - A61L2300/43 take precedence)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compositions of a cyclooxygenase inhibitor and a calcium channel antagonist in a liquid carrier. The composition may be administered the urinary tract during urological diagnostic, interventional, surgical and other medical procedures. One disclosed composition comprises ketoprofen and nifedipine in a liquid irrigation carrier, and includes a solubilizing agent, stabilizing agents and a buffering agent.

## Claims

### Claim 1

A stable composition for us in inhibiting pain/inflammation and spasm, comprising a combination of ketoprofen, nifedipine, propyl gallate and sodium metabisulfite in a liquid carrier, wherein the ketoprofen and nifedipine are included at a ketoprofen to nifedipine molar ratio of between 10:1 to 1:10.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the liquid carrier comprises an aqueous solvent.

### Claim 3 (depends on 2)

The composition of claim 2, wherein the composition further comprises polyethylene glycol 400 as a cosolvent.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the composition further comprises a citric acid buffer.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the ketoprofen and nifedipine are included at a ketoprofen to nifedipine molar ratio of between 5:1 to 1:5.

### Claim 6 (depends on 5)

The composition of claim 5, wherein the ketoprofen and nifedipine are included at a ketoprofen to nifedipine molar ratio of between 4:1 to 1:1.

### Claim 7 (depends on 6)

The composition of claim 6, wherein the ketoprofen and nifedipine are included at a ketoprofen to nifedipine molar ratio of 3:1 plus or minus 20%.
